Pasadena-based Arrowhead Research said Wednesday that it has boosted its stake in Ablaris Therapeutics, a firm developing treatments for obesity. According to Arrowhead Research, it invested $1.3M in a second close of a Series A financing round for Ablaris. The total amount of the round was $2.9M. As part of the funding, Arrowhead now owns 64 percent of Ablaris. The technology from Ablaris was licensed from the MD Anderson Cancer Center. Arrowhead launched Ablaris in December of 2010. More information »